Clinical Efficacy and Safety of SB309, a Biosimilar Recombinant Human Erythropoietin, in the Management of Anemia

Biosimilars
doi 10.2147/bs.s28708
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Clinical Efficacy and Safety of Tevagrastim® (XM02), a Biosimilar Recombinant Human Granulocyte Colony-Stimulating Factor

Biosimilars
2013English

Recombinant Human Erythropoietin vs Transfusions in the Treatment of Anemia of Prematurity

Archives of Pediatrics & Adolescent Medicine
1994English

Efficacy and Safety of Intravenously Administered Iron Sucrose With and Without Adjuvant Recombinant Human Erythropoietin for the Treatment of Resistant Iron-Deficiency Anemia During Pregnancy

American Journal of Obstetrics and Gynecology
GynecologyObstetrics
2001English

97 Cost-Benefit Analysis of Prevention of Neonatal Anemia With Recombinant Human Erythropoietin in Premature Infants

Pediatric Research
Child HealthPediatricsPerinatology
2004English

Treating Renal Anaemia With Recombinant Human Erythropoietin: Practical Guidelines and a Clinical Algorithm.

BMJ
1990English

Psy111 - Pharmacoeconomic Evaluation of Biosimilar Recombinant Alpha-Epoetin in the Treatment of Anemia in Hemodialysis Patients

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Treatment of Anemia in Low Risk Myelodysplastic Syndromes With Granulocyte–macrophage Colony-Stimulating Factor Plus Recombinant Human Erythropoietin

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
1999English

Selective Use of Recombinant Human Erythropoietin in Pregnant Patients With Severe Anemia or Nonresponsive to Iron Sucrose Alone

Fetal Diagnosis and Therapy
Nuclear MedicineRadiologyChild HealthGynecologyPerinatologyImagingObstetricsMedicinePediatricsEmbryology
2009English

Human Recombinant Erythropoietin in Asphyxia Neonatorum: Pilot Trial

Pediatrics
Child HealthPediatricsPerinatology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy